Milestone Scientific (MLSS)
XASE:MLSS
Want to see MLSS full AI Analyst Report?
MLSS Stock Chart & Stats
$0.29
$0.17(16.41%)
At close: 4:00 PM EST
$0.29
$0.17(16.41%)
Day’s Range― - ―
52-Week Range$0.22 - $0.95
Previous CloseN/A
Volume1.27M
Average Volume (3M)172.66K
Market Cap
$34.35M
Enterprise Value$33.88M
Total Cash (Recent Filing)$1.19M
Total Debt (Recent Filing)$985.35K
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Aug 18, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding88,075,170
10 Day Avg. Volume233,274
30 Day Avg. Volume172,658
Financial Highlights & Ratios
PEG Ratio-0.21
Price to Book (P/B)7.97
Price to Sales (P/S)2.50
P/FCF Ratio-7.64
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue3.80
Enterprise Value/Gross Profit5.41
Enterprise Value/Ebitda-7.81
Forecast
1Y Price Target
$1.00Price Target Upside244.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.05
Revenue Forecast (FY)$9.91M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsA sustained ~72% gross margin indicates strong unit economics for Milestone's offerings. This durable product-level profitability provides room for operating leverage as revenue scales, making it materially easier to convert revenue growth into operating income once fixed costs are controlled.
Material Operating Expense ReductionsManagement delivered structural (>30%) opex cuts that narrowed losses ~58%. Permanent cost discipline reduces cash burn and extends runway, improving the credibility of the company's stated path to cash-flow breakeven in early 2027 and lowering financing dependency over the next 2–6 months.
Completed $2.15M FinancingThe April private placement meaningfully strengthens near-term liquidity, funding sales, inventory and digital marketing initiatives. This financing improves the balance sheet runway to execute commercial expansion plans and reduces immediate dilution pressure from emergency financings.
Bears Say
Persistent Negative Cash FlowConsistent operating and free cash outflows indicate the business consumes cash rather than generates it, eroding equity and forcing reliance on external financing. Persistent negative cash flow constrains reinvestment capacity and raises execution risk if capital markets tighten.
Sharp Trailing Revenue DeclineA nearly 25% TTM revenue decline weakens operating leverage and undermines the path to sustainable profitability. Declining top-line trends reduce the benefit of high gross margins and make achieving the company's breakeven targets more dependent on successful commercial execution.
CompuFlo Reimbursement & Commercialization RiskCompuFlo's revenue scaling hinges on reimbursement classification and MAC engagement; delays or unfavorable outcomes could slow clinician adoption and utilization. Given CompuFlo's small absolute revenues today, reimbursement timing is a structural bottleneck for nonlinear growth.
Milestone Scientific News
MLSS FAQ
What was Milestone Scientific’s price range in the past 12 months?
Milestone Scientific lowest stock price was $0.22 and its highest was $0.95 in the past 12 months.
What is Milestone Scientific’s market cap?
Milestone Scientific’s market cap is $34.35M.
When is Milestone Scientific’s upcoming earnings report date?
Milestone Scientific’s upcoming earnings report date is Aug 18, 2026 which is in 75 days.
How were Milestone Scientific’s earnings last quarter?
Milestone Scientific released its earnings results on May 14, 2026. The company reported -$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.01.
Is Milestone Scientific overvalued?
According to Wall Street analysts Milestone Scientific’s price is currently Undervalued.
Does Milestone Scientific pay dividends?
Milestone Scientific does not currently pay dividends.
What is Milestone Scientific’s EPS estimate?
Milestone Scientific’s EPS estimate is -0.01.
How many shares outstanding does Milestone Scientific have?
Milestone Scientific has 88,075,170 shares outstanding.
What happened to Milestone Scientific’s price movement after its last earnings report?
Milestone Scientific reported an EPS of -$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.286%.
Which hedge fund is a major shareholder of Milestone Scientific?
Currently, no hedge funds are holding shares in MLSS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Milestone Scientific Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.94%
12-Months-Change
Fundamentals
Return on Equity
-166.28%
Trailing 12-Months
Asset Growth
-12.38%
Trailing 12-Months
Company Description
Milestone Scientific
Milestone Scientific Inc. designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates in two segments, Dental and Medical. Its products include CompuDent and STA Single Tooth Anesthesia System that are used for all dental procedures that require local anesthetic. The company also offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances; and disposable injection handpiece for the tactile control during the injection. In addition, it provides CompuFlo Epidural, a computer controlled anesthesia system for use in various medical applications. Further, the company offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines. Milestone Scientific Inc. was incorporated in 1989 and is headquartered in Livingston, New Jersey.
MLSS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a cautiously positive outlook: management delivered meaningful expense reductions (>$1.3M, >30% YoY) and materially narrowed operating and net losses (both improved ~58%), while early traction in CompuFlo (medical revenue up >100% and roughly $108k in Q1), strong digital lead generation (152 leads), >50 reimbursement claims submitted, expansion of distributor and ambassador programs, and a $2.15M financing bolster the growth case. Key near-term risks remain—flat overall revenue for the quarter, a $200k shipping disruption, modest gross margin decline, CompuFlo's small absolute revenue base, and dependence on Medicare/MAC reimbursement timing and utilization to unlock nonlinear growth. Given that the positive operational improvements, financing, and early commercial traction outweigh the execution and reimbursement risks at this stage, the overall sentiment is constructive but cautious.View all MLSS earnings summariesMLSS Stock 12 Month Forecast
Average Price Target
$1.00
▲(244.83% Upside)
Technical Analysis
Retractable Technologies
―
Precision Optics Corporation
―
Nephros
―
Femasys
―
NexGel Inc
―
Ownership Overview
10.10% Insiders
2.98% Mutual Funds
0.39% Other Institutional Investors
84.18% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---